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March 12, 2015 marked the 10th anniversary of World Kidney
Day (WKD), an initiative of the International Society of
Nephrology and the International Federation of Kidney
Foundations. Since its inception in 2006, WKD has become
the most successful effort ever mounted to raise awareness
among decision-makers and the general public about the
importance of kidney disease. Each year WKD reminds us
that kidney disease is common, harmful, and treatable. The
focus of WKD 2015 is on chronic kidney disease (CKD) in
disadvantaged populations. This article reviews the key
links between poverty and CKD and the consequent impli-
cations for the prevention of kidney disease and the care of
kidney patients in these populations.
Chronic kidney disease is increasingly a global public
health problem and is a key determinant of poor health
outcomes. There is compelling evidence that disadvan-
taged communities (e.g., communities with low resources,
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marked increases in the burden of unrecognized and un-
treated CKD. The entire population of some low- and mid-
dle-income countries could be considered disadvantaged,
although further discrimination on the basis of local factors
creates a position of extreme disadvantage for certain
population groups (e.g., peasants, people living in certain
rural areas, women, the elderly, religious minorities). The
fact that, even in developed countries, racial and ethnic
minorities bear a disproportionate burden of CKD and have
worse outcomes suggest there is much to learn beyond the
traditional risk factors that contribute to CKD-associated
complications.1
Approximately 1.2 billion people live in extreme poverty
worldwide. Poverty negatively influences healthy behav-
iors, health care access, and environmental exposuredall
of these factors contribute to health care disparities2
(Table 1). The poor are more susceptible to disease because
of lack of access to goods and services (in particular clean
water and sanitation), lack of information about preventive
behaviors, adequate nutrition, and reduced access to
health care.3Fabriques 1B, 1000, Brussels, Belgium.
f the World Kidney Day Steering Committee are Philip Kam Tao Li,
va, Luca Segantini, Paul Shay, Miguel C. Riella, Charlotte Osafo,
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Table 1 Possible mechanisms by which poverty increases the burden of disease.
Health behavior Access to health care Biological factors Enviromental factors
 Lack of information on
preventive behaviors
 Lack of knowledge on
how best to respond to
an episode of illness
 Health beliefs and
unhealthy behaviors
 Lack of access to health care
 Greater distance from health
care providers
 Lack of out-of-pocket
resources
 Low birth weight
 Genetic predisposition
 Cumulative biological
risk profiles
 Inadequate nutrition
 Increased exposure to pollutants
 Increased exposure to communicable
diseases
 Lack of clean water and sanitation
2 EditorialCKD in developed countries
In the United States, ethnic minorities have a higher inci-
dence of end-stage renal disease (ESRD), despite similar
prevalence rates for early stages of CKD.4 Poor outcomes
such as ESRD are 1.5e4 times higher among minorities
(e.g., African-Americans, Latinos and Native Ameri-
cans).2,5e7 Poverty further increases the disparity in ESRD
rates with African-Americans being at greater risk.8 In the
United Kingdom, the rates of treated ESRD are higher in
ethnic minority groups and are higher with increasing social
deprivation.9 In Singapore, the CKD prevalence is similarly
higher among the Malays and Indians than among the Chi-
nese, and socioeconomic and behavioral factors account for
70e80% of the excess risk.10
The ESRD incidence is also higher among the less
advantaged indigenous populations in developed countries.
Canadian First Nations people experience ESRD at rates
2.5e4 times higher than in the general population.11 In
Australia, the increase in the number of indigenous people
starting renal replacement therapy (RRT) during the past
25 years exceeded that of the nonindigenous population by
3.5-fold; this is largely because of a disproportionate (> 10-
fold) difference in ESRD due to type II diabetic nephropa-
thy, a disease largely attributable to lifestyle issues such as
poor nutrition and lack of exercise.12 Indigenous pop-
ulations also have a higher incidence of ESRD due to
glomerulonephritis and hypertension.13 Compared to the
general population in the United States, the ESRD inci-
dence rate is higher in Guam and Hawaii, where the pro-
portion of indigenous people is high; this rate is also driven
primarily by diabetic ESRD.14 Native Americans have a
greater prevalence of albuminuria and higher ESRD inci-
dence rate.15e18 Nearly three-quarters of all incident ESRD
cases among this population are attributable to type II
diabetes.CKD in developing countries
Poverty-related factors such as infectious diseases sec-
ondary to poor sanitation, inadequate supply of safe water,
environmental pollutants, and high concentrations of dis-
ease-transmitting vectors continue to have an important
role in the development of CKD in low-income countries.
The rates of diabetic nephropathy are rising, although
chronic glomerulonephritis and interstitial nephritis are
among the principal causes of CKD in many countries. Of
note is the emergence of HIV-associated nephropathy as
the major cause of CKD in sub-Saharan Africa.19A high prevalence of CKD of unknown etiology has been
reported in rural agricultural communities in Central
America, Egypt, India, and Sri Lanka. Male farm workers are
disproportionately affected. The clinical presentation sug-
gests interstitial nephritis, which is confirmed by renal bi-
opsy. The strong association with farm work has led to
suggestions that exposure to agrochemicals, dehydration,
and the consumption of contaminated water may be
responsible.20 In addition, the use of traditional herbal
medications is common and frequently associated with CKD
among the poor.21,22 In Mexico, CKD prevalence among the
poor is two- to three-fold higher than among the general
population, and the etiology of CKD is unknown in 30% of
ESRD patients.23e26
Low birth weight and risk of CKD in
disadvantaged populations
An association between low birth weight (LBW) primarily
due to nutritional factors and kidney disease has been
described in disadvantaged populations. The frequency of
LBW is more than double in the aboriginal population than
in the nonaboriginal population in Australia. The high
prevalence of albuminuria in the nonaboriginal population
has been linked to a low number of nephrons associated
with LBW.27,28 Morphometry studies of kidney biopsies in
aboriginals show glomerulomegaly that is perhaps second-
ary to nephron deficiency, which may predispose them to
glomerulosclerosis.29,30 A correlation between LBW and
CKD has also been described in poor African-Americans and
Caucasians living in the southeastern United States.31 In an
Indian cohort, LBW and early malnutrition were similarly
associated with the later development of metabolic syn-
drome, diabetes, and diabetic nephropathy.32 The finding
of a high prevalence of proteinuria, elevated blood pres-
sure, and CKD of unknown etiology in South Asian children
may also be explained by this mechanism.33,34
Disparities in access to RRT
A recent analysis showed that 2.6 million people globally
were on dialysis in 2010; among these, 93% were in high or
upper middle-income countries. By contrast, the number of
people requiring RRTwas an estimated 4.9e9 million, which
suggests that at least 2.3 million people died prematurely
because of lack of access to RRT. Even though diabetes and
hypertension increase the burden of CKD, the current pro-
vision of RRT is linked largely to two factors: the per capita
gross national product and a patient’s age, which suggest
Editorial 3that poverty is a major disadvantage for receiving RRT. By
2030, the number of people receiving RRT around the world
is projected to increase to 5.4 million. Most of this increase
will be in the developing countries of Asia and Africa.35
Access to RRT in the emerging world depends mostly on
health care expenditures and the economic strength of in-
dividual countries with the relationship between income
and access to RRT nearly linear in low- and middle-income
countries.19,36 In Latin America, the RRT prevalence and
kidney transplantation rates are significantly correlated
with gross national income and health expenditure.37
However, in India and Pakistan, < 10% of all ESRD patients
have access to RRT.38 In addition, developing countries have
low transplant rates because of a combination of low levels
of infrastructure; geographical remoteness; lack of legisla-
tion governing brain death; religious, cultural, and social
constraints; and commercial incentives that favor dialysis.39
There are also differences in utilization of renal
replacement modalities between indigenous and nonindig-
enous groups in developed countries. In Australia and New
Zealand, the proportion of people receiving home dialysis is
considerably lower among indigenous people. At the end of
2007 in Australia, 33% of nonindigenous people requiring
RRT were receiving home-based dialysis therapies,
compared to 18% of aboriginal people. In New Zealand, 62%
of nonindigenous RRT population utilized home-based
dialysis, but only 42% of Maori/Pacific Islanders did so.12
The rate of kidney transplantation is also lower in disad-
vantaged communities. Maori and Pacific people are only
25% as likely to get a transplant as European New Zea-
landers, and the proportion of indigenous people who un-
dergo transplantation and had a functioning kidney
transplant is lower among aboriginal Australians (12%) than
among nonindigenous Australians (45%). In the United
Kingdom, white individuals from socially deprived areas,
South Asians, and blacks were all less likely to receive a
pre-emptive renal transplant or living donor transplant,
compared to their more affluent white counterparts.9 A
multinational study found that, compared with white pa-
tients, an aboriginal patient’s likelihood of receiving a
transplant for was 77% lower in Australia and New Zealand,
and 66% lower in Canadian First Nations individuals.40
Disparities in renal care are more evident in developing
nations. Data from India shows that there are fewer ne-
phrologists and nephrology services in the poorer states. As
a result, people living in these states are likely to receive
less care.41 In Mexico, the fragmentation of the health care
system has resulted in unequal access to RRT. In the state of
Jalisco, the acceptance and prevalence rates [327 per
million population (pmp) and 939 pmp, respectively] were
higher in the more economically advantaged insured pop-
ulation than for patients without medical insurance (99
pmp and 166 pmp, respectively). The transplant rate also
was dramatically different at 72 pmp for people with health
insurance and 7.5 pmp for people without it.42The bidirectional relationship between
poverty and CKD
In addition to having a higher disease burden, the poor have
limited access to resources for meeting treatment costs. Alarge proportion of patients who are forced to meet the
expensive ESRD treatment costs by incurring out-of-pocket
expenditure are forced into extreme poverty. In one Indian
study, > 70% of patients undergoing kidney transplantation
experienced catastrophic health care expenditures.43
Entire families experience the impact of this through job
loss and interruptions in the education of children, etc.
Outcomes
Theoverallmortality rates amongpeoplewhodo receiveRRT
are higher in the indigenous, minority, and uninsured pop-
ulations, even after adjusting for comorbidities. The hazard
ratios for death on dialysis relative to nonindigenous people
are 1.4 for aboriginal Australians and New Zealand Maori.44
The Canadian First Nations patients achieve target levels for
Blood Pressure and mineral metabolism less frequently.45 In
the United States, living in predominantly black neighbor-
hoods is associated with higher than expected mortality
rates on dialysis and an increased time to transplantation.46
Black patients on peritoneal dialysis similarly have a higher
risk of death or technique failure, compared to whites.47
In Mexico, the mortality on peritoneal dialysis is three-
fold higher among the uninsured population, compared to
Mexican patients receiving treatment in the United States,
and the survival rate is significantly lower in this population
than in the insured Mexican population.48 By contrast, in
India nearly two-thirds of patients are unable to continue
dialysis beyond the first 3 months because of financial
reasons.49
Summary
The increased burden of CKD in disadvantaged populations
is because of global factors and population-specific issues.
Low socioeconomic status and poor access to care
contribute to health care disparities and exacerbate the
negative effects of genetic or biologic predisposition.
Providing appropriate renal care to these populations re-
quires a two-pronged approach: (1) expanding the reach of
dialysis through the development of low-cost alternatives
that can be practiced in remote locations, and (2) imple-
menting and evaluating cost-effective prevention strate-
gies. Kidney transplantation should be promoted by
expanding deceased donor transplant programs and using
inexpensive generic immunosuppressive drugs. The mes-
sage of WKD 2015 is that a concerted attack against dis-
eases that lead to ESRD could end the unacceptable
relationship between CKD and disadvantage in these com-
munities by increasing community outreach, providing
better education, and improving economic opportunity and
access to preventive medicine for people at highest risk.
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